Aspen’s Stephen Saad on South Africa’s vaccination rollout
Saad shares his insights on the pharmaceutical industry, the distribution of the vaccine and threat of Covid-19 variants.
Stephen Saad
Aspen outlays plans post disposal of contaminated J&J vaccines
Aspen was extremely disappointed to learn over the past weekend that specific batches of the J&J vaccines manufactured were contaminated.
Inside Covid-19: More bad news for AstraZeneca; vaccine for dogs; #Covid in your eyes, ears; Twitter censorship
Dr Simone Donati shares how the coronavirus goes easily undetected in normal Covid-19 tests by entering the human body through the eyes.
Aspen delivers on objectives, slashes debt burden
Pharmaceutical giant Aspen Pharmacare expects earnings from continuing operations to increase for its half-year results to 31 December 2020.
Aspen buys plant-derived menopause drug
Aspen has purchased a women’s health drug, without generic competition. Aspen now has exclusive rights to relauch Cenestin® in the USA.
Aspen brings J&J Covid-19 vaccine to SA for manufacture
Aspen joins forces with J&J for Covid-19 vaccine manufacture in South Africa, where trials have been running since June this year.
Market strategy is what’s seriously lacking at Aspen – Ted Black
Isn’t it high time for Stephen Saad to get the brains of his key operating managers out of bed … and to light an ATO fire under their ASSEtS?
Aspen: why profits and margins are only half the story – Ted Black
The prime issue facing Aspen today is its asset productivity. Over the last three years, for every Rand of assets, the firm generated only 29 cents of sales.
Time to invest in SA pharma stock Aspen? Listen to CEO Stephen Saad #BestofBizNews
Alec Hogg chats to Aspen CEO Stephen Saad about the company’s excellent prelim results and Saad’s desire to take Aspen further into vaccine territory.
Aspen share price slumps as sale of European business falls through
Aspen fell the most in four months after the South African drugmaker said talks to sell a European business had ended, a blow to investors looking for progress on debt reduction.